Mantle cell lymphoma treatment offers options if patients relapse after CAR T-cell therapy, from bispecific antibodies, antibody drug conjugates, and other emerging therapies.

Like many cancers, mantle cell lymphoma can vary in how quickly it develops and its severity. As Szubanski's cancer has been described as "fast-moving" and is already stage 4, it appears that it ...

AstraZeneca’s Calquence has expanded its FDA approval to include first-line treatment of mantle cell lymphoma. The regulatory decision makes Calquence the first BTK inhibitor approved as an ...

More information: LBA-6 Lack of Benefit of Autologous Hematopoietic Cell Transplantation (auto-HCT) in Mantle Cell Lymphoma (MCL) Patients (pts) in First Complete Remission (CR) with Undetectable ...

SAN DIEGO — Mantle cell lymphoma patients who go into deep remission from a first therapy may not get any benefit from a follow-up transplant of their stem cells, according to a new study.

December 19, 2007 (Atlanta) — Results obtained with an intensive immunotherapy regimen in mantle-cell lymphoma are so good that they suggest that a cure is in sight, said Christian Geisler, MD ...

Mantle cell lymphoma (MCL) is a rare form of cancer that affects B cells. B cells are a type of white blood in your immune system. MCL is part of a larger group of cancers called ...

Mantle cell lymphoma (MCL) represents a relatively uncommon, heterogeneous lymphoma associated with limited overall survival. Targeting of the B-cell receptor pathway in relapsed disease with covalent ...

Mantle cell lymphoma is a pretty complicated disease. Lots of different things go on. Since then, many people have now described the C481S mutations happening in mantle cell lymphoma.

The FDA approved two oncology regimens on Jan. 16.One is for a subset of patients with colorectal cancer and the other for treatment of patients with mantle cell lymphoma.

Mantle cell lymphoma is a rare, aggressive type of non-Hodgkin lymphoma arising from malignant B cells in the mantle zone of lymph nodes. It accounts for about 5% of lymphoma cases, is more common ...